Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection

Kidney International

Volumn 79, Issue 10, 2011, Pages 1131-1137

  Kimball, Pamela M ^a   Baker, Melissa A ^a   Wagner, Mary B ^a   King, Anne ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

chronic rejection; donor specific antibody; flow crossmatching; post transplant antibody monitoring

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CHRONIC GRAFT REJECTION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOSURVEILLANCE; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SINGLE ANTIGEN BASED LUMINOMETRY; SOLID PHASE SYNTHESIS; SURGICAL RISK;

EID: 79955591882     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.556     Document Type: Article

References (30)

1. Bosmans J, Ysebaert D, Verpooten G. Chronic allograft nephropathy: what have we learned from protocol biopsies? Transplant 2008; 85: S38-S41. (Pubitemid 351521160)
2. Gloor J, Cosio F, Lager D et al. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008; 7: 1367-1373. (Pubitemid 351989489)
3. Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
4. Terasaki P, Cai J. Human leukocytes antigen antibodies and chronic rejection: from association to causation. Transplant 2008; 86: 377-383.
5. Terasaki P, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438-443. (Pubitemid 38282302)
6. Kimball P, Wagner B, King A et al. Comparison of two drug regimens upon clinical outcome among renal transplant recipients with positive flow crossmatches. Clin Transplant 2002; 16: 290-294. (Pubitemid 34830846)
7. Iiham M, Winkler S, Coates E et al. Clinical significance of a positive flow crossmatch on the outcomes of cadaveric renal transplants. Transplant Proc 2008; 40: 1839-1843.
8. Amico P, Honger G, Mayr M et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplant 2009; 87: 1681-1688.
9. Eng H, Bennett G, Tsiopelas E et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8: 2335-2342.
10. Ho E, Vailescu E, Colovai A et al. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. Transplant Immunol 2008; 20: 61-67.
11. Ozawa M, Terasaki P, Lee J et al. 14th international HLA and immunogenetics workshop: report on the prospective chronic rejection project. Tissue Antigens 2007; 69: 174-179. (Pubitemid 46625879)
12. Opelz G, Dohler B, Susal C. Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Human Immunol 2009; 70: 627-630.
13. Bartel G, Regele H, Wahrmann M et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8: 2652-2660.
14. Issa N, Cosio F, Gloor J et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplant 2008; 86: 681-685.
15. Campos E, Tedesco-Silva H, Machado P et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316-2320. (Pubitemid 44359416)
16. Lenaers J, Christiaans M, Voorter C et al. Relevance of posttransplant flow cytometric T and B cell crossmatches in tacrolimus-treated renal transplant patients. Transplant 2006; 82: 1142-1147. (Pubitemid 44748015)
17. Zhang Q, Liang L, Gjertson D et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplant 2005; 79: 591-598. (Pubitemid 40365888)
18. Lachmann N, Terasaki P, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplant 2009; 87: 1505-1513.
19. Mao Q, Terasaki P, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five year longitudinal study. Am J Transplant 2007; 7: 864-871. (Pubitemid 46481194)
20. Scornik J, Guerra G, Schold J et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007; 7: 1808-1814. (Pubitemid 46905444)
21. Burns J, Cornell L, Perry D et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
22. Susal C, Dohler B, Sadeghi M et al. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplant 2009; 87: 1367-1371.
23. Lee P, Zhu L, Terasaki P et al. HLA specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplant 2009; 88: 568-574.
24. Mizutani K, Terasaki P, Rosen A et al. Serial ten year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265-2272. (Pubitemid 41648475)
25. Bartel G, Wahrmann M, Exner M et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8: 41-49.
26. Martin L, Guignier F, Mousson C et al. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplant 2003; 76: 305-400.
27. Kimball P, Rhodes C, King A et al. Flow crossmatching identifies patients at risk for postoperative elaboration of cytotoxic antibodies. Transplant 1998; 65: 444-446. (Pubitemid 28095981)
28. Solez K, Colvin R, Racusen L et al. Banff '07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
29. Stegall M, Gloor J, Winters J et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific antibody. Am J Transplant 2006; 6: 346-351. (Pubitemid 43382170)
30. Tambur A, Ramon D, Kaufman D et al. Perception versus reality: virtual crossmatch-how to overcome some of the technical and logistic limitations. Am J Transplant 2009; 9: 1886-1893.